Philadelphia—Long-term treatment with low-dose colchicine significantly decreases major adverse cardiovascular (CV) events among patients who have had a recent heart attack, investigators from COLCOT (the Colchicine Cardiovascular Outcomes Trial) reported at the American Heart Association’s (AHA’s) 2019 Scientific Sessions.
During the study, which was published in The New England Journal of Medicine (2019 Nov 16. [Epub ahead of print]), investigators randomized